Tscan Historical Financial Ratios

TCRX Stock

USD 2.05 0.01 0.49%

Tscan Therapeutics is promptly reporting on over 89 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.72, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.36 will help investors to properly organize and evaluate Tscan Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

About Tscan Financial Ratios Analysis

Tscan TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Tscan Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Tscan financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Tscan Therapeutics history.

Tscan Therapeutics Financial Ratios Chart

At this time, Tscan Therapeutics' PTB Ratio is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to rise to 0.36 in 2025, whereas Price To Sales Ratio is likely to drop 19.85 in 2025.

Price To Sales Ratio Payables Turnover Capex To Revenue Cash Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Tscan Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tscan Therapeutics sales, a figure that is much harder to manipulate than other Tscan Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Tscan Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Tscan Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.At this time, Tscan Therapeutics' PTB Ratio is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to rise to 0.36 in 2025, whereas Price To Sales Ratio is likely to drop 19.85 in 2025.

	2022	2023	2024	2025 (projected)
Current Ratio	6.94	6.51	7.49	9.02
Net Debt To EBITDA	0.57	0.51	0.59	0.56

Current Ratio Net Debt To E B I T D A

Tscan Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield
Price To Sales Ratio		-0.96	-0.89	0.59	0.81	0.73	-0.96	1.0	0.8	0.05	0.91	-0.7	0.99	-0.79	-0.56	-0.69	-0.2	-0.88	0.84	0.11	0.99	-0.55	-0.95	0.12	-0.87	0.64
Ptb Ratio	-0.96		0.78	-0.49	-0.68	-0.65	1.0	-0.95	-0.68	-0.33	-0.88	0.77	-0.96	0.69	0.3	0.73	-0.08	0.7	-0.96	-0.4	-0.97	0.29	0.99	-0.39	0.68	-0.55
Book Value Per Share	-0.89	0.78		-0.65	-0.9	-0.41	0.78	-0.9	-0.92	0.11	-0.87	0.33	-0.82	0.98	0.6	0.33	0.23	0.87	-0.61	0.18	-0.81	0.61	0.83	0.07	0.89	-0.65
Free Cash Flow Yield	0.59	-0.49	-0.65		0.91	0.4	-0.49	0.6	0.89	0.01	0.83	0.03	0.55	-0.69	-0.38	0.04	-0.12	-0.6	0.36	-0.23	0.57	-0.38	-0.61	0.11	-0.6	1.0
Operating Cash Flow Per Share	0.81	-0.68	-0.9	0.91		0.48	-0.68	0.82	0.99	-0.12	0.92	-0.16	0.75	-0.91	-0.59	-0.17	-0.26	-0.84	0.5	-0.27	0.76	-0.6	-0.77	-0.05	-0.85	0.9
Capex To Depreciation	0.73	-0.65	-0.41	0.4	0.48		-0.65	0.71	0.41	-0.2	0.54	-0.78	0.8	-0.25	-0.63	-0.81	-0.49	-0.74	0.54	0.03	0.79	-0.61	-0.59	-0.07	-0.69	0.46
Pb Ratio	-0.96	1.0	0.78	-0.49	-0.68	-0.65		-0.95	-0.68	-0.33	-0.88	0.77	-0.96	0.69	0.3	0.73	-0.08	0.7	-0.96	-0.4	-0.97	0.29	0.99	-0.39	0.68	-0.55
Ev To Sales	1.0	-0.95	-0.9	0.6	0.82	0.71	-0.95		0.81	0.04	0.91	-0.68	0.99	-0.81	-0.56	-0.67	-0.19	-0.88	0.83	0.1	0.98	-0.56	-0.95	0.11	-0.87	0.64
Free Cash Flow Per Share	0.8	-0.68	-0.92	0.89	0.99	0.41	-0.68	0.81		-0.08	0.92	-0.13	0.73	-0.94	-0.55	-0.13	-0.2	-0.81	0.51	-0.25	0.74	-0.56	-0.77	-0.02	-0.82	0.88
Roic	0.05	-0.33	0.11	0.01	-0.12	-0.2	-0.33	0.04	-0.08		0.21	-0.2	0.06	0.06	0.8	-0.08	0.95	0.42	0.55	0.9	0.12	0.8	-0.34	0.99	0.44	0.06
Net Income Per Share	0.91	-0.88	-0.87	0.83	0.92	0.54	-0.88	0.91	0.92	0.21		-0.42	0.87	-0.85	-0.37	-0.39	0.01	-0.75	0.79	0.12	0.89	-0.37	-0.94	0.29	-0.75	0.85
Payables Turnover	-0.7	0.77	0.33	0.03	-0.16	-0.78	0.77	-0.68	-0.13	-0.2	-0.42		-0.77	0.15	0.26	0.99	0.08	0.48	-0.78	-0.51	-0.76	0.24	0.65	-0.26	0.44	-0.06
Capex To Revenue	0.99	-0.96	-0.82	0.55	0.75	0.8	-0.96	0.99	0.73	0.06	0.87	-0.77		-0.71	-0.55	-0.76	-0.21	-0.86	0.85	0.17	1.0	-0.54	-0.94	0.14	-0.84	0.6
Cash Per Share	-0.79	0.69	0.98	-0.69	-0.91	-0.25	0.69	-0.81	-0.94	0.06	-0.85	0.15	-0.71		0.51	0.14	0.14	0.78	-0.53	0.21	-0.7	0.52	0.77	0.04	0.8	-0.68
Pocfratio	-0.56	0.3	0.6	-0.38	-0.59	-0.63	0.3	-0.56	-0.55	0.8	-0.37	0.26	-0.55	0.51		0.35	0.91	0.88	-0.04	0.68	-0.5	1.0	0.29	0.73	0.88	-0.36
Interest Coverage	-0.69	0.73	0.33	0.04	-0.17	-0.81	0.73	-0.67	-0.13	-0.08	-0.39	0.99	-0.76	0.14	0.35		0.19	0.53	-0.72	-0.42	-0.75	0.33	0.61	-0.14	0.48	-0.04
Capex To Operating Cash Flow	-0.2	-0.08	0.23	-0.12	-0.26	-0.49	-0.08	-0.19	-0.2	0.95	0.01	0.08	-0.21	0.14	0.91	0.19		0.61	0.32	0.79	-0.15	0.91	-0.11	0.9	0.62	-0.1
Pfcf Ratio	-0.88	0.7	0.87	-0.6	-0.84	-0.74	0.7	-0.88	-0.81	0.42	-0.75	0.48	-0.86	0.78	0.88	0.53	0.61		-0.48	0.35	-0.83	0.88	0.71	0.34	1.0	-0.61
Days Payables Outstanding	0.84	-0.96	-0.61	0.36	0.5	0.54	-0.96	0.83	0.51	0.55	0.79	-0.78	0.85	-0.53	-0.04	-0.72	0.32	-0.48		0.63	0.88	-0.03	-0.94	0.6	-0.46	0.43
Income Quality	0.11	-0.4	0.18	-0.23	-0.27	0.03	-0.4	0.1	-0.25	0.9	0.12	-0.51	0.17	0.21	0.68	-0.42	0.79	0.35	0.63		0.21	0.7	-0.34	0.89	0.39	-0.15
Roe	0.99	-0.97	-0.81	0.57	0.76	0.79	-0.97	0.98	0.74	0.12	0.89	-0.76	1.0	-0.7	-0.5	-0.75	-0.15	-0.83	0.88	0.21		-0.49	-0.95	0.2	-0.81	0.62
Ev To Operating Cash Flow	-0.55	0.29	0.61	-0.38	-0.6	-0.61	0.29	-0.56	-0.56	0.8	-0.37	0.24	-0.54	0.52	1.0	0.33	0.91	0.88	-0.03	0.7	-0.49		0.28	0.74	0.88	-0.36
Pe Ratio	-0.95	0.99	0.83	-0.61	-0.77	-0.59	0.99	-0.95	-0.77	-0.34	-0.94	0.65	-0.94	0.77	0.29	0.61	-0.11	0.71	-0.94	-0.34	-0.95	0.28		-0.4	0.69	-0.66
Return On Tangible Assets	0.12	-0.39	0.07	0.11	-0.05	-0.07	-0.39	0.11	-0.02	0.99	0.29	-0.26	0.14	0.04	0.73	-0.14	0.9	0.34	0.6	0.89	0.2	0.74	-0.4		0.37	0.17
Ev To Free Cash Flow	-0.87	0.68	0.89	-0.6	-0.85	-0.69	0.68	-0.87	-0.82	0.44	-0.75	0.44	-0.84	0.8	0.88	0.48	0.62	1.0	-0.46	0.39	-0.81	0.88	0.69	0.37		-0.6
Earnings Yield	0.64	-0.55	-0.65	1.0	0.9	0.46	-0.55	0.64	0.88	0.06	0.85	-0.06	0.6	-0.68	-0.36	-0.04	-0.1	-0.61	0.43	-0.15	0.62	-0.36	-0.66	0.17	-0.6

Click cells to compare fundamentals

Tscan Therapeutics Account Relationship Matchups

Tscan Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	(6.17)	0.67	0.37	2.53	2.28	2.4
Book Value Per Share	(1.7)	6.72	4.13	2.3	2.07	1.72
Free Cash Flow Yield	(0.0277)	(0.54)	(1.9)	(0.17)	(0.19)	(0.2)
Operating Cash Flow Per Share	(0.12)	(2.04)	(2.77)	(0.94)	(1.08)	(1.13)
Capex To Depreciation	3.45	2.99	0.82	0.59	0.67	0.64
Pb Ratio	(6.17)	0.67	0.37	2.53	2.28	2.4
Free Cash Flow Per Share	(0.29)	(2.45)	(2.94)	(0.98)	(1.13)	(1.19)
Net Income Per Share	(1.04)	(2.03)	(2.74)	(1.36)	(1.56)	(1.64)
Payables Turnover	7.07	1.89	1.76	37.13	33.42	35.09
Cash Per Share	1.4	6.75	4.99	2.93	2.63	2.84
Pocfratio	(86.62)	(2.21)	(0.56)	(6.23)	(5.61)	(5.89)
Capex To Operating Cash Flow	(1.4)	(0.2)	(0.0635)	(0.0513)	(0.0461)	(0.0485)
Pfcf Ratio	(36.06)	(1.84)	(0.53)	(5.93)	(5.34)	(5.6)
Days Payables Outstanding	51.62	193.58	206.91	9.83	11.3	10.74
Roe	0.61	(0.3)	(0.66)	(0.59)	(0.68)	(0.65)
Ev To Operating Cash Flow	(77.57)	0.98	(0.0486)	(5.57)	(5.01)	(5.26)
Pe Ratio	(10.06)	(2.21)	(0.57)	(4.29)	(3.86)	(4.05)
Ev To Free Cash Flow	(32.3)	0.82	(0.0457)	(5.29)	(4.77)	(5.0)
Earnings Yield	(0.0994)	(0.45)	(1.77)	(0.23)	(0.27)	(0.28)
Net Debt To E B I T D A	1.09	3.43	0.57	0.51	0.59	0.56
Current Ratio	2.09	7.76	6.94	6.51	7.49	9.02
Tangible Book Value Per Share	(1.7)	6.72	4.13	2.3	2.07	1.72
Graham Number	6.32	17.54	15.96	8.39	7.55	8.17
Shareholders Equity Per Share	(1.7)	6.72	4.13	2.3	2.07	1.72
Debt To Equity	(0.18)	0.0376	0.86	0.61	0.55	0.58
Capex Per Share	0.17	0.42	0.18	0.048	0.0432	0.041
Graham Net Net	(2.3)	5.61	0.85	1.08	0.97	0.68
Interest Debt Per Share	0.3	0.25	3.62	1.47	1.32	0.94
Debt To Assets	0.15	0.0321	0.43	0.34	0.31	0.17
Enterprise Value Over E B I T D A	(9.38)	1.05	(0.0539)	(4.26)	(3.84)	(4.03)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Tscan Historical Financial Ratios

About Tscan Financial Ratios Analysis

Tscan Therapeutics Financial Ratios Chart

Price To Sales Ratio

Payables Turnover

Capex To Revenue

Tscan Therapeutics fundamentals Correlations

Tscan Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tscan Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Tscan Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Roe	+ 1.0	Capex To Revenue
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Pfcf Ratio

Roe	- 0.97	Pb Ratio
Roe	- 0.97	Ptb Ratio
Days Payables Outstanding	- 0.96	Pb Ratio
Capex To Revenue	- 0.96	Pb Ratio
Days Payables Outstanding	- 0.96	Ptb Ratio
Capex To Revenue	- 0.96	Ptb Ratio